MARKET

IMA

IMA

ImageneBio
NASDAQ
5.29
-0.62
-10.49%
After Hours: 5.41 +0.12 +2.27% 19:49 05/08 EDT
OPEN
5.68
PREV CLOSE
5.91
HIGH
5.90
LOW
5.28
VOLUME
75.40K
TURNOVER
--
52 WEEK HIGH
18.00
52 WEEK LOW
3.940
MARKET CAP
59.67M
P/E (TTM)
-0.4918
1D
5D
1M
3M
1Y
5Y
1D
ImageneBio, Inc. reports Q1 results
Seeking Alpha · 1d ago
Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 5/8/26?
TipRanks · 1d ago
ImageneBio price target lowered to $24 from $30 at Leerink
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), ImageneBio (IMA) and Natera (NTRA)
TipRanks · 2d ago
ImageneBio Q1 EPS $(0.95) Misses $(0.70) Estimate
Benzinga · 2d ago
Press Release: ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
Dow Jones · 2d ago
Why Is Vanguard Total Stock Market (VTI) ETF Up Today, 5/7/26?
TipRanks · 2d ago
Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 5/6/26?
TipRanks · 3d ago
More
About IMA
ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.

Webull offers ImageneBio Inc stock information, including NASDAQ: IMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMA stock methods without spending real money on the virtual paper trading platform.